The Former Head of the Human Genome Project Joins InSilico Medicine, Inc. in the War on Aging as the Chair of the SAB

Share Article

Charles Cantor, PhD, professor emeritus at Boston University and former principal scientist of the Human Genome Project joined the Science Advisory Board of InSilico Medicine, Inc.

InSilico Medicine, Inc.

InSilico Medicine, Inc is a Baltimore-based bioinformatics and drug discovery company specializing in cancer and aging research and personalized medicine in age-related diseases.

InSilico Medicine, Inc. announced today that Charles Cantor, Ph.D. will chair its Scientific Advisory Board.

Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer-reviewed articles, authored and co-authored more than 50 U.S. and international patents. He is also an author of the first genomics textbook, “Genomics: The Science and Technology of the Human Genome Project” and the three-volume textbook “Biophysical Chemistry”.

“Professor Cantor’s discoveries and leadership are already helping save lives and improve human health span. What is less known is his interest in areas related to aging including the complex and multi-year research projects in isotopically-fortified organic compounds and advanced diagnostics using the cell-free nucleic acids. He is the role model for the many research scientists aspiring to utilize resources available in the private sector, accelerate scientific research without the many formal constraints and budgetary limitations of academia and turn their discoveries into practical projects. We are honored to have Charles join our advisory board”, said Alex Zhavoronkov, PhD, CEO of InSilico Medicine, Inc.

Dr. Cantor is the co-founder of Sequenom, Inc, a company engaged in non-invasive prenatal diagnostics and co-founder of Retrotope, a company developing isotopically-fortified organic compounds to bolster stress resistance and combat age-related diseases and acts as a consultant for several companies within the biotechnology industry. He is professor emeritus at the Boston University, distinguished adjunct professor at the University of California Irvine and adjunct professor at the Moscow Institute of Physics and Technology and at Scripps Research Institute. Dr. Cantor was previously the chair and professor of the department of biomedical engineering and biophysics, and director of the Center for Advanced Biotechnology at Boston University, and his research laboratory remains active.

“Aging is one of the most pressing problems facing the economies of the developed countries and there is an urgent need for new ways to increase productive longevity and screening the known drugs for their geroprotective properties and personalizing anti-cancer and aging-suppressive regiments using genetic and epigenetic analysis is one of the low hanging fruits in applied aging research. I am pleased to join the SAB of this international team dedicated to develop working solutions for both aging and age-related diseases”, said Charles Cantor, PhD, chair of the Science Advisory Board of InSilico Medicine, Inc.

Dr. Cantor was the chairman of Genetics and Development at Columbia University College of Physicians & Surgeons, and Professor of Molecular Biology, University of California, Berkeley.

He earned his bachelor's degree in chemistry at Columbia College, and his doctorate at the University of California Berkeley.

About InSilico Medicine, Inc.

Insilico Medicine, Inc. is a Baltimore-based bioinformatics and drug discovery company specializing in cancer and aging research and personalized medicine in age-related diseases. The company is developing models and softwares to predict the efficacy of the various targeted drugs in oncology and extrapolated these methods to evaluate the possible geroprotective properties of the many drugs with known molecular targets. The mission of InSilico Medicine is to find working solutions to treat, cure and prevent age-related diseases and aging itself through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine. This mission will be achieved within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility. For more information please visit .

Contact @ Insilico Medicine, Inc.:

InSilico Medicine, Inc.
Johns Hopkins University Eastern Campus
B301, 1101 East 33rd Street
Baltimore, MD 21218

Qinsong Zhu, PhD
Chief Operating Officer

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Qingsong Zhu, PhD
Visit website